Saturday, April 20, 2024

After A Decade on Roche’s OCREVUS, 77% with Relapsing Multiple Sclerosis Stayed Disability-Free, and 92% Could Walk Unaided

Similar articles

New clinical and real-world data for Roche’s OCREVUS were presented at the 9th Joint ECTRIMS-ACTRIMS Meeting (European and Americas Committees for Treatment and Research in Multiple Sclerosis), highlighting the drug’s impact on preventing disability progression and maintaining mobility in both relapsing and progressive forms of multiple sclerosis (MS). OCREVUS is the first and only disease-modifying treatment (DMT) in MS to benefit both people with relapsing or primary progressive MS (RMS or PPMS). It now has 10 years of follow-up data from its Phase III trials.

After 10 years of continuous OCREVUS treatment, 77% of patients with RMS were free from disability progression, and 92% of RMS patients could still walk unassisted. In patients with PPMS, 36% were free from disability progression, and 80% of those treated continuously with OCREVUS over 10 years could still walk.

New safety data from over 6,000 patients across 12 clinical trials reinforce the medicine’s consistent long-term safety profile over 10 years. Serious infections and malignancy rates remain within the range reported for MS patients in real-world registries, and no new or unexpected safety signals were observed.

The drug also demonstrated its safety and efficacy in Black and Hispanic/Latinx people with MS, who often experience more severe disease progression and disability. The CHIMES trial, the first-ever clinical trial focused exclusively on these populations, showed that OCREVUS controlled disease activity and disability progression. Approximately half of the patients achieved no evidence of disease activity at one year, with no new safety signals observed.

Additionally, real-world analyses indicate that women with MS treated with OCREVUS do not have an increased risk of adverse pregnancy or infant outcomes. Outcomes showed no significant increase in risks compared to the general population.

Roche continues to advance clinical research programs to expand the scientific understanding of MS, reduce disability worsening, and improve the treatment experience for those living with the disease. More than 30 ongoing OCREVUS clinical trials are aimed at furthering the understanding of MS and its progression. OCREVUS is approved in more than 100 countries worldwide.

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest article